Vanda Pharmaceuticals (VNDA) Expected to Announce Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) will likely be releasing its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect Vanda Pharmaceuticals to post earnings of $0.05 per share and revenue of $45.13 million for the quarter. Vanda Pharmaceuticals has set its FY 2030 guidance at EPS and its FY 2025 guidance at EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. On average, analysts expect Vanda Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock traded up $0.02 during trading hours on Monday, hitting $4.59. 402,550 shares of the stock traded hands, compared to its average volume of 758,626. Vanda Pharmaceuticals has a 1 year low of $3.85 and a 1 year high of $6.75. The stock has a market capitalization of $270.51 million, a price-to-earnings ratio of -14.34 and a beta of 0.72. The firm's 50 day moving average price is $4.56 and its 200-day moving average price is $4.67.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were acquired at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now directly owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. The trade was a 0.43 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders purchased a total of 32,000 shares of company stock valued at $151,180 in the last ninety days. Insiders own 8.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating on the stock. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, April 1st.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.